Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec names head of gene therapy

Olivier Danos joins from Kadmon Pharmaceuticals
Olivier Danos Biogen Idec

Biogen Idec has appointed Dr Olivier Danos as senior VP, gene therapy.

Dr Danos will lead Biogen Idec's gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. Danos will also identify potential collaborations for the company.

“Olivier is a true pioneer in the field,” said Dr Douglas Williams, executive VP, R&D. “We believe that his expertise will help accelerate our development of a world-class gene therapy platform that combines our growing internal capabilities with collaborations with leading research organizations across the globe.”

Dr Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011.

Prior to Kadmon, Dr Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris.

His career also includes a spell as president of the European Society of Gene and Cell Therapy.

24th September 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics